Abstract
Bepotastine besilate is a selective histamine1-receptor antagonist and mast cell stabilizer with inhibitory effects on eosinophilic activity. To evaluate the safety and efficacy of 1.5% bepotastine besilate ophthalmic solution in alleviating nonocular symptoms induced by a conjunctival allergen challenge (CAC), a clinical model of allergic conjunctivitis. This was a single-center, double-masked, randomized, placebo-controlled clinical trial performed from March 1 to April 4, 2007. Patients 10 years or older with a history of allergic conjunctivitis and a reproducible, positive, clinical response to a CAC were eligible. Patients received either placebo or 1.5% bepotastine besilate, 1 drop in each eye. After 15 minutes, 8 hours, or 16 hours after dosing, a CAC was performed and patients evaluated nonocular symptoms using standardized grading scales. Seventy-one patients were enrolled in the study, and 66 comprised the per protocol population. A clinically meaningful reduction (> or = 1.0 unit) compared to placebo was achieved for rhinorrhea and nasal congestion at most time points after 1.5% bepotastine besilate instillation at 8 hours before a CAC test. Significant reductions (P < or = .05) in mean values were seen with 1.5% bep...Continue Reading
References
Oct 11, 1990·The New England Journal of Medicine·J BousquetP Godard
Jul 1, 1997·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·N YatoH Narita
May 20, 1998·Biological & Pharmaceutical Bulletin·O KaminumaK Ikezawa
Sep 8, 1998·Pharmacology·M UenoA Koda
Oct 6, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·M B Abelson
May 25, 1999·Acta Ophthalmologica Scandinavica. Supplement·M B Abelson
Mar 15, 2002·Current Allergy and Asthma Reports·A Keane-Myers
Apr 16, 2002·Clinical Therapeutics·Mark B Abelson, Allen P Kaplan
Aug 17, 2002·Clinical Therapeutics·Bob Q LanierMartin K Kägi
Dec 28, 2002·Clinical Therapeutics·H Jerome Crampton
May 14, 2003·Archives of Ophthalmology·Mark B AbelsonNaveed B K Shams
Jun 7, 2003·Current Allergy and Asthma Reports·Mark B Abelson, Oliver Loeffler
Mar 5, 2004·Clinical Therapeutics·Mark B AbelsonScott M Whitcup
May 6, 2004·Current Opinion in Allergy and Clinical Immunology·Inga HansenKarl Hörmann
Nov 13, 2004·The Journal of Allergy and Clinical Immunology·Erwin W Gelfand
Nov 26, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·George W OuslerMark B Abelson
Jun 23, 2005·Current Medical Research and Opinion·Mark B AbelsonStella M Robertson
Feb 24, 2006·The American Journal of Medicine·Bruce M Prenner, Eric Schenkel
Oct 4, 2006·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Josefine Gradman, Ole D Wolthers
Oct 18, 2006·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·William BergerEli O Meltzer
Dec 10, 2008·Allergy and Asthma Proceedings·Lanny J RosenwasserKathryn Kennedy
Feb 17, 2009·Expert Opinion on Pharmacotherapy·Kazuhiro HashiguchiKimihiro Okubo
Citations
Jun 9, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jon I WilliamsUNKNOWN Bepotastine Besilate Ophthalmic Solutions Study Group
Nov 7, 2013·Expert Opinion on Pharmacotherapy·Leonard BieloryAndrea McMunn
May 7, 2015·Expert Opinion on Pharmacotherapy·Mark B AbelsonLisa M Smith
Jan 22, 2011·Current Medical Research and Opinion·Gail Torkildsen, Arthur Shedden
Nov 1, 2011·The Journal of Allergy and Clinical Immunology·F Estelle R Simons, Keith J Simons
Feb 27, 2016·International Forum of Allergy & Rhinology·Sule ComertAli Fuat Kalyoncu
Sep 13, 2018·Expert Opinion on Pharmacotherapy·Ismael Carrillo-MartinVes Dimov
Feb 6, 2014·Allergy & Rhinology·Milton M Hom, Leonard Bielory